DNA X, Inc. (SONM) SEC Filings, Feb-Apr 2026

DNA X, Inc. filed an amended current report to clarify the accounting treatment of its acquisition of DNA X LLC. The company had purchased 100% of the membership interests in DNA X LLC for 223,201 shares of its common stock, representing 19.99% of its outstanding common shares at issuance.

After a detailed financial analysis, DNA X determined that this transaction does not involve a “significant amount of assets” for purposes of Item 2.01 of the Exchange Act rules. As a result, the company concluded the transaction did not trigger Item 2.01 disclosure and will not provide the financial statements or pro forma financial information that were referenced in its earlier report.

DNA X, Inc. large shareholder DNA Holdings Venture Inc. filed an initial ownership report showing direct holdings of 223,201 shares of Common Stock. This Form 3 establishes that DNA Holdings Venture Inc. is a more than ten percent owner of DNA X, Inc. as of the reported date.

DNA Holdings Venture Inc., Scott Walker, and Brock Pierce reported a significant stake in DNA X, Inc. on Schedule 13D. They beneficially own 223,201 shares of common stock, representing about 19.99% of DNA X’s outstanding shares based on 1,116,286 shares outstanding as of December 15, 2025.

The stake stems from a membership interest purchase where DNA X acquired 100% of DNA X LLC for 223,201 shares, alongside a $1,200,000 convertible promissory note that is convertible at $5.50 per share starting six months after issuance. DNA Holdings also received a put option tied to DNA X LLC’s trading volume or revenue performance before June 30, 2026.

So long as DNA Holdings owns at least 5% of DNA X’s common stock, it can designate one officer and one board nominee, and it has agreed to vote its shares in favor of a specified asset purchase agreement under an irrevocable proxy through the earlier of January 15, 2026 or that agreement’s termination.

DNA X, Inc. shareholder Laurence W. Lytton filed an amended Schedule 13G reporting a significant passive stake in the company’s common stock. As of the event date, he beneficially owned 148,290 shares, representing 9.96% of the 1,488,268 shares outstanding.

Lytton reports sole voting and dispositive power over 109,402 shares and shared power over 38,888 shares. The filing notes additional warrants to purchase 22,222 shares are excluded because they are subject to a 4.99% beneficial ownership limitation. He certifies the holdings are not intended to change or influence control of DNA X, Inc.

1 Main Capital Management and related reporting persons report that they now beneficially own 0 shares, or 0.0%, of Sonim Technologies common stock as of December 31, 2025. All four reporting entities list zero sole or shared voting and dispositive power over Sonim shares. The filing confirms they own 5 percent or less of the class and certifies the position is not held to change or influence control of Sonim Technologies.

DNA X, Inc. reported that its Chief Financial Officer, Clayton Crolius, received a grant of 35,000 restricted stock units of common stock on February 9, 2026 at a price of $0.00 per share. These units vest in equal monthly installments over one year, conditioned on continued service.

Each restricted stock unit represents the right to receive one share of common stock. After this grant, Crolius beneficially owns 36,719 securities, consisting of 1,719 shares of common stock and 35,000 unvested restricted stock units. The filing notes these figures reflect a 1-for-18 reverse stock split effective October 27, 2025.

DNA X, Inc. Acting CEO and director Michael C. Mulica reported an equity compensation grant. On February 9, 2026, he was awarded 50,000 restricted stock units of common stock at a price of $0.00 per unit as a service-based grant.

The units vest in equal monthly installments over one year, contingent on his continued service. Following this grant, he beneficially owns 54,071 securities, consisting of 4,071 shares of common stock and 50,000 unvested restricted stock units. These figures reflect a 1-for-18 reverse stock split that took effect on October 27, 2025.

DNA X, Inc. appointed executive chairman Mike Mulica as acting chief executive officer and principal executive officer effective February 9, 2026. Mulica’s annual base salary was increased to $450,000, and he received 50,000 restricted stock units vesting monthly over one year, along with up to 12 months of COBRA premium reimbursement if his employment terminates and he elects continuation coverage.

The company also amended Chief Financial Officer Clay Crolius’s employment agreement, confirming that the previously announced asset sale completed on January 23, 2026 is a triggering event under his contract. Crolius was granted 35,000 RSUs vesting monthly over one year and may receive up to six months of COBRA premium reimbursement following a qualifying termination.

DNA X, Inc. reported major leadership changes, with chief executive officer Peter Liu resigning as CEO and director on January 30, 2026, and chief commercial officer Charles Becher resigning effective January 29, 2026. Both entered separation and release agreements that include general releases of claims against the company.

Liu will receive a total cash severance of $855,000, now split into two payments, while Becher will receive a $250,000 lump-sum severance. The board appointed Scott Walker, a beneficial owner of DNA Holdings Venture, Inc., as a director under DNA Holdings’ right to designate a board member tied to prior investment agreements.